"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 8 | 2 | 10 |
| 2000 | 1 | 1 | 2 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 5 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 6 | 0 | 6 |
| 2005 | 4 | 0 | 4 |
| 2006 | 8 | 2 | 10 |
| 2007 | 6 | 1 | 7 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 0 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 5 | 10 |
| 2014 | 9 | 4 | 13 |
| 2015 | 7 | 0 | 7 |
| 2016 | 2 | 6 | 8 |
| 2017 | 13 | 2 | 15 |
| 2018 | 12 | 3 | 15 |
| 2019 | 12 | 6 | 18 |
| 2020 | 18 | 7 | 25 |
| 2021 | 9 | 7 | 16 |
| 2022 | 4 | 16 | 20 |
| 2023 | 6 | 21 | 27 |
| 2024 | 23 | 12 | 35 |
| 2025 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv. 2025 Mar 11; 9(5):1171-1180.
-
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025 Feb 25; 9(4):696-703.
-
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood. 2025 Feb 20; 145(8):823-839.
-
Development and validation of predictive models of early immune effector cell-associated hematotoxicity. Blood Adv. 2025 Feb 11; 9(3):606-616.
-
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations. Neuro Oncol. 2025 Feb 10; 27(2):352-368.
-
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 03; 31(3):529-542.
-
Gene editing of CD3 epsilon to redirect regulatory T?cells for adoptive T?cell transfer. Mol Ther. 2025 Mar 05; 33(3):997-1013.
-
EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 2025 Jan 28; 9(2):270-279.
-
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Apr; 72(4):e31557.
-
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).